2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1949 Preliminary efficacy and safety of glofitamab plus chidamide in high-risk relapsed/refractory DLBCL: A prospective phase II study

Wei Li, Lanfang Li2, Xianming Liu3, Zhengzi Qian4, Shiyong Zhou5, Huilai Zhang, PhD6
1 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
2 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
3 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
4 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
5 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
6 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China

Background Glofitamab has demonstrated activity in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), but deep and durable responses are not achieved in all patients. Chidamide, an oral selective histone deacetylase inhibitor with immunomodulatory properties, may provide a rationale for combination with CD20×CD3 T-cell engagement. We report preliminary efficacy and safety results of glofitamab plus chidamide in patients with R/R DLBCL.

Methods This prospective, single-center, open-label, single-arm phase II study (NCT06570447) is enrolling 22 adults with R/R DLBCL after ≥2 prior systemic therapies. Following obinutuzumab pretreatment, glofitamab was administered (2.5 mg C1D8, 10 mg C1D15, 30 mg C2–12 D1; 21-day cycles) alongside twice-weekly oral chidamide 20 mg. The primary endpoint was complete response (CR) rate at end of treatment (EOT). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Responses were assessed per Lugano 2014 and adverse events (AEs) per CTCAE v5.0.

Results As of July 28, 2026, 17 patients had received study treatment and were included in the modified intention-to-treat (mITT) and safety populations. The cohort had high-risk features: median age was 70 years (range, 41–81), all patients (100%) had stage IV disease, and 58.8% had bone marrow involvement. The median International Prognostic Index (IPI) score was 4 (range, 2–5), with 14 patients (82.4%) having a score ≥3. Patients had received a median of 2 prior lines of therapy (range, 2–7); 1 patient (5.9%) had received prior CAR T-cell therapy, and none had undergone autologous stem cell transplantation. Median treatment exposure was 4 cycles (range, 1–12). At data cutoff, 12 patients had ended study treatment, and 5 remained on treatment. The prespecified EOT CR primary endpoint remained under evaluation because 5 patients were still receiving treatment. In this high-risk cohort, rapid preliminary antitumor activity was observed. In the mITT population, the investigator-assessed ORR based on best overall response was 64.7% (11/17; 95% CI, 38.3%–85.8%), including 2 CRs and 9 partial responses. Median time to first response was 1.2 months (range, 0.5–3.0). After a median follow-up of 6.5 months (95% CI, 4.3–not reached), 12 PFS events and 8 deaths had occurred. Median PFS was 3.9 months (95% CI, 2.1–10.5), and median OS was 8.8 months (95% CI, 5.7–12.0). Treatment-emergent adverse events (TEAEs) occurred in 11 patients (64.7%), and grade ≥3 TEAEs occurred in 3 patients (17.6%). The most common TEAEs were thrombocytopenia (47.1%; grade 3, n=1), anemia (35.3%; all grade 1–2), and leukopenia (23.5%; grade 3, n=2). Cytokine release syndrome (CRS) occurred in 2 patients (11.8%); both events were grade 1. No immune effector cell-associated neurotoxicity syndrome (ICANS) or treatment-related deaths were reported.

Conclusions Rapid preliminary antitumor activity was observed with glofitamab plus chidamide in a high-risk R/R DLBCL population. CRS was low-grade, and no ICANS or treatment-related deaths were reported. The prespecified EOT CR primary endpoint remains under evaluation as patients are still receiving treatment. Completion of enrollment and longer follow-up will further characterize response depth, durability, and safety.

Wei Li: No relevant conflicts of interest to declare.